Rating Change
Leerink Partners analysts initiated coverage on Q32 Bio Inc. (NASDAQ:QTTB) with a rating of Outperform on October 12, 2026.
new coverageNASDAQ:QTTB
Leerink Partners Initiates Coverage on Q32 Bio Inc. (QTTB) with Outperform
Leerink Partners analysts initiated coverage on Q32 Bio Inc. (NASDAQ:QTTB) with a rating of Outperform on October 12, 2026.
At publication ·
What changed
Q32 Bio Inc. (NASDAQ:QTTB) · new coverage
- Firm
- Leerink Partners
- Rating
- Outperform
- Price at event
- $8.68
- Market capitalization
- $39.2M
At a glance
Key takeaways
- Leerink Partners initiated coverage of Q32 Bio Inc. (QTTB) with an Outperform rating on October 12, 2026.
- Q32 Bio trades at $8.68 per share with a market capitalization of $39.2 million in the healthcare sector.
Market Context
Q32 Bio Inc. operates in the Healthcare sector. The stock currently trades at $8.68 with a market capitalization of $39.2M.
Analyst coverage from Leerink Partners provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Q32 Bio Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Q32 Bio Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 12, 2026 | Leerink Partners | Outperform | N/A |
| Sep 28, 2026 | Jefferies | Buy | N/A |
| Aug 24, 2026 | Morgan Stanley | Overweight | N/A |
| Jul 28, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jul 13, 2026 | Oppenheimer | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View QTTB Stock Page
Frequently Asked Questions
What does the Outperform rating mean for QTTB?
A rating of Outperform from Leerink Partners reflects the analyst's outlook on Q32 Bio Inc. (NASDAQ:QTTB). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the QTTB forecast page.